

LAW OFFICES
KILYK & BOWERSOX, P.L.L.C.
Intellectual Property Law

LUKE A. KILYK* (PA, DC)
 LEONARD D. BOWERSOX
 JASBIR SINGH
 MATTHEW T. GILL
 RALPH T. WEBB* (DC, TX, LA)
 SUSANNE M. HOPKINS
 J. MARK KONIECZNY* (MA)

53 A East Lee Street
 WARRENTON, VA 20186

FAIRFAX OFFICE
 3603-E Chain Bridge Road
 Fairfax, Virginia 22030

Of Counsel:
 WILLIAM CHARLES JAMISON

TEL.: (540) 428-1701
 FAC.: (540) 428-1720
 (540) 428-1721

Email: lkilyk@kbpatentlaw.com
 Website: http://www.kbpatentlaw.com

*Admitted only in states indicated

PLEASE DIRECT CORRESPONDENCE TO OUR WARRENTON OFFICE

FACSIMILE TRANSMISSION COVER SHEET

DATE: April 12, 2005

TO: Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

RE: U.S. Patent Application No. 10/062,257
 Entitled: TUMOR ANTIGEN
Our Ref.: 3190-014

FROM: Luke A. Kilyk, Esq. 


FAC. TEL. NO.: 1-703-872-9306

NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 4

Items Attached: Third Supplemental Information Disclosure Statement – 2 pages
 Form PTO 1449 -- 1 page

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on April 12, 2005.

Donald S. Prater
 Name (Print)


 Signature

THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

RECEIVED
CENTRAL FAX CENTER
 APR 12 2005

APR 12 2005

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on April 12, 2005.

Donald S. Prater
Name (Print)

Donald S. Prater
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	ITOH)	Examiner:	Unassigned
Application No.:	10/062,257)	Group Art Unit:	1646
Filed:	February 1, 2002)	Confirmation No.:	8619
Docket No.	3190-014)	Customer No.:	33432

For: TUMOR ANTIGEN

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 12, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided. Applicants also bring to the Examiner's attention co-pending U.S. Patent Application No. 10/498,075.

This Third Supplemental Information Disclosure Statement is being submitted after expiration of the three-month period following filing of the above-captioned application, but before an Office Action on the merits and before any Final Office Action or Notice of Allowance.

Should a first Office Action cross in the mail with the filing of this Third Supplemental Information Disclosure statement, then applicants respectfully petition under 37 C.F.R. § 1.97(c) to consider the documents set forth in the Third Supplemental Information Disclosure Statement.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and

✓ Third Supplemental Information Disclosure Statement
U.S. Patent Application No. 10/062,257


1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-014
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: Form PTO-1449

Page 1 of 1

FORM PTO-1449 (REV 7-80)			Atty. Docket No. 3190-014			Application No. 10/062,257	
INFORMATION DISCLOSURE STATEMENT			Applicant: ITOH				
			Filing Date: February 1, 2002			Group Art Unit: 1646	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE, IF APPROPRIATE
		2004/0141992 A1	07/22/04	Itoh et al.	424	185.1	
		2005/0019341 A1	01/27/05	Itoh et al.	424	185.1	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER				DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							